The FDA approved new formulation of Herceptin for subcutaneous use
On Feb. 28, 2019, the U.S. Food and Drug Administration (FDA) approved trastuzumab and hyaluronidase-oysk injection,for subcutaneous use (Herceptin Hylecta, Genentech).
Herceptin Hylecta is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, for the treatment of HER2-overexpressing breast cancer.
Tags:
Source: U.S. Food and Drug Administration
Credit:
